Dr Subrahmanyam Vangala is currently Co-Founder and Chief Executive Officer at ReaGene Biosciences Private Limited (Bangalore, India), ReaGene Innovations Private Ltd (Hyderabad, India). He is an experienced pharma scientist and executive with more than 25 years of leadership experience with increasing responsibilities, at global pharma in USA (Wyeth, JNJ, Purdue Pharma and Shire) and Contract Research Organizations in India (Sai Life and Advinus). His industrial experience was focused on, but not limited to, new drug discovery and development with expertise in DMPK, Bioanalytical, Clinical Pharmacology and Toxicology. His Pharma experience produced more than 30 IND submissions, with at least six marketed molecules drugs including Zaleplon (short acting sedative-hypnotic), Tygacil (4th generation tetracycline antibiotic against vancomycin and methicillin resistant bacteria), Canagliflozin (targeted SGLT-2 inhibitor for type II diabetes), Tibsovo (targeted IDH1 inhibitor for refractory myeloid leukemia). Other areas he gained experience include predictive clinical drug-drug interactions, pre-formulation development, drug repurposing, specialty pharmaceuticals, generics, biologics/biosimilars, medical devices, pharmacogenomics, metabolomics and alternatives to animals in research. He participated in several due-diligence activities involving in-licensing activities.

He received his PhD Degree in Biochemical Mechanisms of Chemical Carcinogenesis from the Department of Biochemistry, Memorial University of Newfoundland, Canada. He conducted his postdoctoral research in Molecular Toxicology department at University of Colorado at Boulder, and continued as a Specialist Scientist in Molecular Toxicology at School of Public Health, University of California, Berkeley. During his PhD and postdoctoral research, he extensively studied DNA damage of electrophilic and free radical intermediates, of environmental pollutants and other mutagens/carcinogens for their risk assessment and related public health concerns.

His current research interests include developing 3D bio printed human tissues as Alternatives to Animal models to support drug discovery, nutraceutical, agrochemical, cosmetics and environmental pollutant research.

He is on the ICMR expert committee for Alternatives to Animals in Research and primary advisor/contributor of ICMR article on Indian Perspectives of Alternatives to Animals in Research. He is also on the Executive Committee for Society for Alternatives to Animals in India. He brings with him, unique insights into translational research for risk assessment. He is on the scientific advisory board of Bioagile therapeutics Pvt Ltd, Tranalab Pvt Ltd and on the editorial board of journals related to toxicology and analytical research. He has nearly 60 publications in peer-reviewed journals including several invited book chapters. He has chaired several international symposia in drug discovery, predictive toxicology, idiosyncratic drug toxicity and DMPK and invited keynote speaker at many conferences/symposia.